Exploring a role for organic transporter 3 in the mechanism of action of drugs of abuse

探索有机转运蛋白 3 在滥用药物作用机制中的作用

基本信息

  • 批准号:
    9788402
  • 负责人:
  • 金额:
    $ 19.06万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-09-15 至 2021-08-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT Co-abuse of cocaine and alcohol is one of the most common, and dangerous drug pairings, as evidenced by their concurrent use being a major cause for emergency hospitalization. Thus, this drug combination is not only a serious health threat to the individual user, but a major public health burden. Currently, there are no effective treatments for addiction to cocaine and ethanol, underscoring the vital need to understand the mechanistic basis of this highly addictive drug pairing in order to discover new targets for therapeutic intervention. It is well-known that cocaine and ethanol each increase extracellular levels of dopamine (DA), serotonin (5-HT), and norepinephrine (NE), biogenic amine neurotransmitters that are strongly linked to the rewarding properties of drugs. Cocaine does this by inhibiting the high-affinity, low-capacity transporters for these neurotransmitters, DAT, SERT, and NET, respectively. However, the mechanisms by which ethanol does so are unclear. It is known that ethanol inhibits uptake of DA, 5-HT, and NE, however our published data, together with literature evidence, show this inhibition to be DAT-, SERT-, and NET-independent. Organic cation transporter 3 (OCT3) is a low-affinity, high-capacity transporter for DA, 5-HT, and NE, and is emerging as an important player in regulation of biogenic amine homeostasis. Interestingly, recent reports show that corticosterone, a blocker of OCT3, enhances cocaine-induced DA signaling and potentiates reinstatement of cocaine seeking via an OCT3-dependent mechanism. Moreover, we found that OCT3 expression is increased in mice lacking SERT (-/-), and that ethanol, and corticosterone, both inhibit 5-HT clearance in SERT-/- mice to a much greater extent than in their wild-type counterpart. Together, these findings raise the possibility that ethanol may interact with OCT3 to inhibit uptake of biogenic amines, thereby increasing the addictive properties of cocaine, and propagating the concurrent use of these drugs. To this end, the studies proposed in this exploratory R21 will test the overarching hypothesis that one mechanism by which ethanol increases extracellular DA, 5-HT and NE is by inhibition of their uptake via OCT3, and that this inhibition enhances the increase in biogenic amines produced by cocaine, which blocks their uptake via DAT, SERT and NET. Importantly, we will determine the OCT3-dependency of ethanol’s ability to enhance the rewarding properties of cocaine. We will use pharmacological and genetic approaches, combined with in vivo neurochemistry, and behavioral assays relevant for reward. Regardless of the outcome of these exploratory studies, results will fill fundamental knowledge gaps about the mechanism(s) through which ethanol inhibits uptake of biogenic amines and enhances rewarding effects of cocaine. Results from these studies will improve our understanding of mechanisms that make the abuse potential of concurrent alcohol and cocaine use so high. Importantly, these studies will form an essential platform on which to base larger scale studies probing novel molecular targets, putatively OCT3, for medications to treat abuse of alcohol and cocaine.
摘要 可卡因和酒精的共同滥用是最常见和最危险的药物配对之一, 它们的同时使用是急诊住院的主要原因。因此,该药物组合不是 这不仅对个人使用者构成严重的健康威胁,而且是一个重大的公共健康负担。目前没有 可卡因和乙醇成瘾的有效治疗,强调了了解 这种高度成瘾性药物配对的机制基础,以发现新的治疗靶点。 干预众所周知,可卡因和乙醇各自增加多巴胺(DA)的细胞外水平, 5-羟色胺(5-HT)和去甲肾上腺素(NE),生物胺神经递质,与 药物的奖励特性。皮质醇通过抑制高亲和力,低容量的转运蛋白来实现这一点。 这些神经递质,DAT,SERT和NET。然而,乙醇 这一点还不清楚。已知乙醇抑制DA、5-HT和NE的摄取,然而我们发表的数据, 与文献证据一起,表明这种抑制是DAT,SERT和NET独立的。有机 阳离子转运蛋白3(oct 3)是一种低亲和力、高容量的DA、5-HT和NE转运蛋白, 作为生物胺稳态调节的重要参与者。有趣的是,最近的报告显示, 皮质酮,一种OCT 3的阻断剂,增强可卡因诱导的DA信号传导, 可卡因寻求通过OCT 3依赖性机制。此外,我们发现OCT 3表达增加, 在缺乏SERT(-/-)小鼠中,乙醇和皮质酮均抑制SERT-/-小鼠中5-HT清除, 比它们的野生型对应物大得多。总之,这些发现提出了一种可能性, 乙醇可以与OCT 3相互作用以抑制生物胺的摄取,从而增加成瘾性。 可卡因的性质,并宣传这些药物的同时使用。为此目的, 这个探索性的R21将检验一个总体假设,即乙醇增加的一种机制 细胞外DA,5-HT和NE是通过抑制它们经由OCT 3的摄取,并且这种抑制增强了细胞外DA,5-HT和NE的表达。 可卡因产生的生物胺增加,从而阻止其通过DAT、SERT和NET的吸收。 重要的是,我们将确定乙醇增强奖励特性的能力对OCT 3的依赖性 可卡因。我们将使用药理学和遗传学方法,结合体内神经化学, 与奖励相关的行为分析。无论这些探索性研究的结果如何, 关于乙醇抑制生物质吸收的机制的基本知识空白 胺和增强可卡因的奖励作用。这些研究的结果将增进我们对 同时使用酒精和可卡因的滥用潜力如此之高的机制。重要的是, 这些研究将形成一个重要的平台,在此基础上进行更大规模的研究, 目标,pupiloct 3,药物治疗滥用酒精和可卡因。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LYNETTE C DAWS其他文献

LYNETTE C DAWS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LYNETTE C DAWS', 18)}}的其他基金

Uptake2 transporters: Novel sex-dependent molecular targets to treat stimulant use disorder
Uptake2转运蛋白:治疗兴奋剂使用障碍的新型性别依赖性分子靶标
  • 批准号:
    10595444
  • 财政年份:
    2023
  • 资助金额:
    $ 19.06万
  • 项目类别:
Organic cation transporter 3: a novel molecular target to treat amphetamine abuse
有机阳离子转运蛋白 3:治疗苯丙胺滥用的新型分子靶点
  • 批准号:
    9808668
  • 财政年份:
    2019
  • 资助金额:
    $ 19.06万
  • 项目类别:
Age-related differences in serotonin clearance: novel targets for antidepressants
血清素清除率与年龄相关的差异:抗抑郁药的新目标
  • 批准号:
    9062518
  • 财政年份:
    2015
  • 资助金额:
    $ 19.06万
  • 项目类别:
The dopamine transporter in eating disorders: Uncovering new therapeutic targets
饮食失调中的多巴胺转运蛋白:发现新的治疗靶点
  • 批准号:
    8771759
  • 财政年份:
    2014
  • 资助金额:
    $ 19.06万
  • 项目类别:
The dopamine transporter in eating disorders: Uncovering new therapeutic targets
饮食失调中的多巴胺转运蛋白:发现新的治疗靶点
  • 批准号:
    8845537
  • 财政年份:
    2014
  • 资助金额:
    $ 19.06万
  • 项目类别:
Organic Cation Transporters as Targets for Novel Antidepressant Drugs
有机阳离子转运蛋白作为新型抗抑郁药物的靶标
  • 批准号:
    8424968
  • 财政年份:
    2012
  • 资助金额:
    $ 19.06万
  • 项目类别:
Serotonin Club Meetings 2012-2016
2012-2016 年血清素俱乐部会议
  • 批准号:
    8446340
  • 财政年份:
    2012
  • 资助金额:
    $ 19.06万
  • 项目类别:
Organic Cation Transporters as Targets for Novel Antidepressant Drugs
有机阳离子转运蛋白作为新型抗抑郁药物的靶标
  • 批准号:
    8969703
  • 财政年份:
    2012
  • 资助金额:
    $ 19.06万
  • 项目类别:
Organic Cation Transporters as Targets for Novel Antidepressant Drugs
有机阳离子转运蛋白作为新型抗抑郁药物的靶标
  • 批准号:
    8262100
  • 财政年份:
    2012
  • 资助金额:
    $ 19.06万
  • 项目类别:
Organic Cation Transporters as Targets for Novel Antidepressant Drugs
有机阳离子转运蛋白作为新型抗抑郁药物的靶标
  • 批准号:
    8581356
  • 财政年份:
    2012
  • 资助金额:
    $ 19.06万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了